Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy offers a distinctive mechanism of action compared to traditional treatments, arising from additional value dimensions that may not be captured in standard health technology assessments. Cancer patients may have the expectation that immunotherapy provides durable, long-term survival gai...

Full description

Bibliographic Details
Main Authors: Remziye Zaim, W. Ken Redekop, Carin A. Uyl-de Groot
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor
non-small cell lung cancer
value assessment
risk preferences
hope
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1027659/full

Similar Items

Similar Items